Bevacizumab Induction
The induction group receives two 28-day cycles of paclitaxel plus bevacizumab before switching to atezolizumab plus nab-paclitaxel. During induction, paclitaxel is given at 90 mg/m2 on days 1, 8, and 15 of each 28-day cycle. During inducti…
1 sources - 6 claims
The induction group receives two 28-day cycles of paclitaxel plus bevacizumab before switching to atezolizumab plus nab-paclitaxel. During induction, paclitaxel is given at 90 mg/m2 on days 1, 8, and 15 of each 28-day cycle. During induction, bevacizumab is given at 10 mg/kg on days 1 and 15 of each induction cycle. Bevacizumab is an anti-VEGF antibody. The trial tests whether bevacizumab plus paclitaxel first can reduce VEGF-mediated resistance before atezolizumab plus nab-paclitaxel. Bevacizumab plus paclitaxel is already a standard treatment option for metastatic triple-negative breast cancer regardless of PD-L1 status.